XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
SEGMENTED INFORMATION
 3 Months Ended
Mar. 31, 2024
SEGMENTED INFORMATION  
SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

 

At March 31, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

 

 

BioNexus Gene Lab Corp.

 

 

 

a Wyoming company

 

 

 

 

 

 

 

 

 

 

 

 

 

100% owned

 

 

100% owned

MRNA Scientific Sdn. Bhd.

(formerly “Bionexus Gene Lab Sdn. Bhd.”),

 

 

Chemrex Corporation Sdn. Bhd.,

a Malaysian company

 

 

a Malaysian Company

 

At March 31, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex.

 

For the three months ended March 31, 2024, segmented (unaudited) revenue and net (loss)/profit (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

MRNA Scientific

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$3,165

 

 

$2,378,686

 

 

$-

 

 

$2,381,851

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(2,252)

 

 

(2,014,568)

 

 

-

 

 

 

(2,016,820)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

913

 

 

 

364,118

 

 

 

-

 

 

 

365,031

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

38,694

 

 

 

163,153

 

 

 

-

 

 

 

201,847

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(80,855)

 

 

(415,629)

 

 

(149,422)

 

 

(645,906)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT FROM OPERATIONS

 

 

(41,248)

 

 

111,642

 

 

 

(149,422)

 

 

(79,028)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,950)

 

 

(2,687)

 

 

(24)

 

 

(4,661)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(43,198)

 

 

108,955

 

 

 

(149,446)

 

 

(83,689)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(20,068)

 

 

-

 

 

 

(20,068)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(43,198))

 

$88,887

 

 

$(149,446)

 

$(103,757)

 

 

MRNA Scientific

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Three months ended March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$7,436

 

 

$2,369,769

 

 

$-

 

 

$2,377,205

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(5,347)

 

 

(2,002,961)

 

 

-

 

 

 

(2,008,308)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS /PROFIT

 

 

2,089

 

 

 

366,808

 

 

 

-

 

 

 

368,897

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

1,126

 

 

 

116,218

 

 

 

-

 

 

 

117,344

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(46,255)

 

 

(383,177)

 

 

(107,440)

 

 

(536,872)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT FROM OPERATIONS

 

 

(43,040)

 

 

99,849

 

 

 

(107,440)

 

 

(50,631)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(666)

 

 

(1,779)

 

 

-

 

 

 

(2,445)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(43,706)

 

 

98,070

 

 

 

(107,440)

 

 

(53,076)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(15,990)

 

 

-

 

 

 

(15,990)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(43,706)

 

$82,080

 

 

$(107,440)

 

$(69,066)

 

 

As of March 31, 2024 and December 31, 2023

 

 

 

Total Assets

 

 

 Total Liabilities

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BGLC & MRNA Scientific

 

$4,535,139

 

 

$4,723,449

 

 

$330,827

 

 

$260,119

 

Chemrex

 

 

6,626,344

 

 

 

6,676,344

 

 

 

1,486,469

 

 

 

1,481,822

 

TOTAL

 

 

11,161,483

 

 

 

11,399,793

 

 

 

1,817,296

 

 

 

1,741,941